explore -WSS

explore

author：Wikipedia 2025-09-29 18:16:01 - browse：68

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Does good food count as health care? Study aims to find out

WSS

CRISPR pioneers react to Casgevy, first gene

One Duchenne patient's bittersweet hope for new treatment

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

In key trial, Verve's treatment lowers cholesterol levels in patients

Weight loss drug costs may need more research, senator suggests

Gain of function research would be limited under House proposal

Wikipedia

explore

Wikipedia

At least 13 dead in Texas as scorching temps continue

Digital health funding stays low as a new reality sets in

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Morphosys mixed study results for blood cancer drug

Continuity nursing helped my family in our darkest PICU moments

NYU radiologists take on the challenge of expensive MRI machines

Walensky prepares to leave CDC — and Congress — behind

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Continuity nursing helped my family in our darkest PICU moments

France's anti

focus

Anthos stroke drug appears safer than common blood thinner

Morphosys mixed study results for blood cancer drug

CRISPR pioneers react to Casgevy, first gene

Why medical students are struggling with mental health

In key trial, Verve's treatment lowers cholesterol levels in patients

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

explore

hotspot

knowledge

entertainment